Page 2 - ஐரோப்பிய சமூகம் ஆஃப் இருதயவியல் காங்கிரஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results
tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.
Empagliflozin Cuts Risk of Hospitalization, Death in HFpEF Patients
empr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from empr.com Daily Mail and Mail on Sunday newspapers.
May 11, 2021
The addition of finerenone to standard medical therapy significantly reduces the risk of cardiovascular mortality and other cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes, according to topline results from FIGARO-DKD announced this week.
Bayer, the maker of the investigational mineralocorticoid receptor antagonist (MRA), announced that the large-scale study met its primary endpoint reduction in the risk of first occurrence of CV mortality, MI, stroke, or heart failure hospitalization in the approximately 7,400 patients randomized in the trial.
The positive study is the second trial showing a benefit of finerenone in patients with CKD and type 2 diabetes. In the FIDELIO-DKD trial, led by George Bakris, MD (University of Chicago, IL), finerenone reduced the risk of kidney failure or death from renal causes, the study’s primary endpoint, and reduced the risk of CV mortality, MI, stroke, or heart failure hospitalization. Unlike
May 03, 2021
The US Food and Drug Administration has approved dapagliflozin (Farxiga; AstraZeneca) to reduce the risk of renal and cardiovascular adverse events in patients with chronic kidney disease (CKD) who are at risk of disease progression, irrespective of whether they have diabetes.
On the strength of the DAPA-CKD trial, which was presented at last year’s virtual European Society of Cardiology Congress, dapagliflozin is now indicated to reduce the risk of declining kidney function, kidney failure, cardiovascular mortality, and hospitalization for heart failure in adults with CKD.
This makes dapagliflozin the first sodium-glucose cotransporter 2 (SGLT2) inhibitor to be approved for the treatment of CKD regardless of diabetes status. Dapagliflozin and other SGLT2 inhibitors were initially developed for patients with type 2 diabetes, but the drugs have shown far-reaching benefits in different patient populations, specifically patients with HF with reduced ejection fraction
FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.